Latest Conference Articles

Results from the CATALYST trial showed patients who received mifepristone had a mean HbA1c reduction of 1.47%,

Nathan Ramsbacher, PharmD, emphasizes that one of the most significant barriers to clinical quality is patients' inability to access crucial medications due to cost.

From 2019 to 2024, GLP-1 prescriptions among pediatric patients with type 2 diabetes increased from 12.3% to 60.9%.

The most frequent barriers to access to glucagon include cost, patient health literacy, and insurance coverage.

Researchers explored the prevalence of obesity-related complications and obesity medication use in US children and young adults with obesity.

The initiative focuses on managing medications for high-risk diabetes patients through a collaborative drug therapy agreement.

Researchers presented an abstract describing current racial disparities in CGM access and wear time to better inform quality improvement efforts.

Researchers explored the impact of a $0 copay program on hemoglobin A1c levels in patients with type 2 diabetes who were also insured by Blue Cross and Blue Shield of Louisiana.

In a retrospective study of obesity-related mortality, researchers explored US death trends before, during, and after the COVID-19 pandemic.

Data presented at ADA 2025 showed patients who received outreach from a clinical pharmacist were more likely to be prescribed safer diabetes regimens.

In a real-world, 6-month analysis, glucagon-like peptide-1 programs with obesity telemedicine behavioral programs resulted in benefits to weight loss and blood pressure.

When compared with adults 45 years and older, those 18 to 44 years are less likely to receive treatment or achieve target goals for cardiometabolic risk factors.

Data presented at ADA’s 85th Scientific Sessions showed patients who received physician education with clinical pharmacist outreach had significantly better A1c levels at 6 months compared to usual care.

Abstract researchers explored whether or not a pharmacist could serve as the lead of a diabetes coaching program, aiming to reduce medical expenditures and A1C levels for at-risk patients.

Check out our coverage from the American Pharmacists Association Annual Meeting and Exposition 2025!

In a session at PQA 2025, presenters discussed the impact of SDoH on health outcomes and how pharmacy teams can identify and address barriers.

Razanne Oueini, PharmD, MSc, CPHQ, discusses how rates of persistence to basal insulin were impacted after the IRA monthly cap.

Michael Hegener, PharmD, BCACP, discusses how workforce development can best address the evolving knowledge, skills, and abilities needed in community pharmacy practice.

Micah Cost, PharmD, MS, CAE, discusses the biggest issues currently impacting the pharmacy profession.

Kaitlin Bates, PharmD, discusses the results of implementing a program used to support standardized pharmacy quality measures.

Michael Hegener, PharmD, BCACP, discusses what workflow changes are essential to support the expansion of patient care services in community pharmacies.

Mitchell Barnett, PharmD, MS, discusses what lessons can be learned from a community pharmacy drug disposal program.

Michael Hegener, PharmD, BCACP, discusses how collaboration with health plans and pharmacy employers can enhance the implementation of practice redesign initiatives.

A conversation with Razanne Oueini, PharmD, MSc, CPHQ, senior manager of Performance Measurement at PQA, at PQA 2025.

A conversation with Micah Cost, PharmD, MS, CAE, CEO of PQA, at PQA 2025.

A conversation with Kaitlin Bates, PharmD, ARHOME Quality Manager at Arkansas Blue Cross and Blue Shield, at PQA 2025.

A conversation with Michael Hegener, PharmD, BCACP, associate professor of Pharmacy at the University of Cincinnati, at PQA 2025.

A conversation with Mitchell Barnett, PharmD, MS, professor of pharmaceutical sciences at Texas A&M University, at PQA 2025.

NBC News Medical Analyst Vin Gupta, MD, joins Drug Topics at NCPDP 2025 to discuss the technological evolution of the pharmacy profession.

Attorneys from The Phoenix Law Group joined Drug Topics at NCPDP 2025 to discuss the current state of pharmacy benefit manager reform and where it may end up in the near future.